Abcam, ab305106, Anti-Riz1 antibody [EPR25164-34] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal RIZ1 antibody. Carrier free. Suitable for IP, Flow Cyt (Intra), ICC/IF, IHC-P, WB and reacts with Human, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25164-34,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:Flow Cyt (Intra), WB, IP, IHC-P, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RIZ1 also known as PRDM2 is a tumor suppressor gene coding for a protein with a mass of approximately 280 kDa. This protein functions mechanically as a histone methyltransferase specifically modifying histone H3 on lysine 9. The structural component of RIZ1 includes a PR domain and a SET domain essential for its methyltransferase activity. This protein gets expressed in various tissues particularly in the brain ovary testis and skeletal muscle.
Biological function summary
The RIZ1 protein plays a significant role in transcriptional regulation and cell cycle arrest. It forms complexes with other proteins allowing it to exert its regulatory functions effectively. These complexes enable RIZ1 to bind DNA and affect chromatin structure which is critical for the transcriptional silencing of genes involved in cell proliferation. By blocking cell cycle progression RIZ1 helps maintain genomic stability ensuring that cells do not grow uncontrollably.
Pathways
RIZ1 protein influences gene expression and cellular processes by interacting with key signaling pathways including the p53 pathway and the retinoblastoma (Rb) pathway. These pathways regulate cell cycle checkpoints and apoptosis where RIZ1 assists in enhancing the tumor suppressive activities of p53 or Rb. Additionally RIZ1 interacts with proteins like MDM2 and E2F to modulate these pathways reinforcing its role in controlling cellular proliferation and survival.
RIZ1 shows strong associations with cancer notably breast cancer and hepatocellular carcinoma. Researchers have observed that RIZ1 expression levels are frequently reduced in these cancers. The interaction between RIZ1 and the retinoblastoma protein links it to these malignancies as loss or inactivation of RIZ1 mitigates its tumor-suppressive functions. This association suggests that therapies targeting pathways involving both RIZ1 and other proteins like p53 might prove beneficial in treating these cancers.